ABIOMED (ABMD) : Gerstein Fisher reduced its stake in ABIOMED by 0.24% during the most recent quarter end. The investment management company now holds a total of 32,426 shares of ABIOMED which is valued at $4,023,742 after selling 77 shares in ABIOMED , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.ABIOMED makes up approximately 0.51% of Gerstein Fisher’s portfolio.
Other Hedge Funds, Including , Scout Investments reduced its stake in ABMD by selling 62,436 shares or 18.83% in the most recent quarter. The Hedge Fund company now holds 269,067 shares of ABMD which is valued at $33,388,524. ABIOMED makes up approx 0.89% of Scout Investments’s portfolio.Oak Ridge Investments reduced its stake in ABMD by selling 59,504 shares or 8.3% in the most recent quarter. The Hedge Fund company now holds 657,789 shares of ABMD which is valued at $79,099,127. ABIOMED makes up approx 1.91% of Oak Ridge Investments’s portfolio. Oregon Public Employees Retirement Fund added ABMD to its portfolio by purchasing 13,211 company shares during the most recent quarter which is valued at $1,566,560. ABIOMED makes up approx 0.03% of Oregon Public Employees Retirement Fund’s portfolio.Quantitative Investment Management reduced its stake in ABMD by selling 30,400 shares or 60.44% in the most recent quarter. The Hedge Fund company now holds 19,900 shares of ABMD which is valued at $2,359,742. ABIOMED makes up approx 0.11% of Quantitative Investment Management’s portfolio. Oakbrook Investments added ABMD to its portfolio by purchasing 3,875 company shares during the most recent quarter which is valued at $450,469. ABIOMED makes up approx 0.02% of Oakbrook Investments’s portfolio.
ABIOMED closed down -0.3 points or -0.24% at $123.39 with 3,14,061 shares getting traded on Monday. Post opening the session at $123.81, the shares hit an intraday low of $123.22 and an intraday high of $124.43 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, ABIOMED reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.